Grants and Contributions:
Grant or Award spanning more than one fiscal year (2017-2018 to 2018-2019).
Bio-therapeutics such as monoclonal antibodies which are widely used for treating life-threatening ailments arex000D
currently manufactured by mammalian cell culture. Large-scale production using mammalian cell culture isx000D
technically challenging and expensive. Bio-pharming, i.e. expression of therapeutic proteins in plant is a novel,x000D
scalable, safe, economical, environment -friendly and promising alternative to mammalian cell culture.x000D
PlantForm Corporation is an Ontario based bio-pharming company with an established track record inx000D
manufacturing tobacco based bio-therapeutics. The company recognises that feedstock pre-treatment beforex000D
product purification could significantly affect the efficiency of the purification process. Such pre-treatment willx000D
target the removal of impurities such as RUBISCO and pigments present in tobacco extract using novelx000D
membrane technology developed in the applicant's research group. Removing these key impurities throughx000D
pre-treatment step is expected to increase the overall purification efficiency and contribute towards increasedx000D
product purity and recovery, and lowering of manufacturing cost.